Daiichi Sankyo owns the fastest-growing oncology engine in the pharma industry. Within Global Business Development, the Strategic Initiatives team brings a science-forward, capital-informed lens to enterprise decision-making for Daiichi Sankyo’s most senior leadership.

The team’s ADC platform has driven breakout oncology growth, but sustaining that trajectory depends on decisions being made right now. They sought a quantified, peer-grounded analytical foundation to sharpen their strategic planning.

Working with Sleuth, the team built a custom peer database covering 15 peers, 1,550+ assets, and 15 years of deal history. From that one foundation, dozens of analytical cuts traceable to source data and ready for direct use in executive conversations. Over $5M in avoided consulting fees. More than 92% reduction in time to output.

The full case study will be coming soon. Follow Sleuth on LinkedIn or X to stay up to date.